Radiolabeling of Theranostic Nanosystems

Das, Sudeep; Imlimthan, Surachet; Airaksinen, Anu J.; Sarparanta, Mirkka

doi:10.1007/978-3-030-58174-9_3

Cited by 2 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other words, the research should always keep in mind that he/she is tracing the NMs with radionuclide or radionuclide-chelator complex on their surface, not their pristine form. ( Das et al, 2021 ).…”

Section: Radiolabeling Strategiesmentioning

confidence: 99%

Radiolabeling of Nanomaterials: Advantages and Challenges

et al. 2021

View full text Add to dashboard Cite

Quantifying the distribution of nanomaterials in complex samples is of great significance to the toxicological research of nanomaterials as well as their clinical applications. Radiotracer technology is a powerful tool for biological and environmental tracing of nanomaterials because it has the advantages of high sensitivity and high reliability, and can be matched with some spatially resolved technologies for non-invasive, real-time detection. However, the radiolabeling operation of nanomaterials is relatively complicated, and fundamental studies on how to optimize the experimental procedures for the best radiolabeling of nanomaterials are still needed. This minireview looks back into the methods of radiolabeling of nanomaterials in previous work, and highlights the superiority of the “last-step” labeling strategy. At the same time, the problems existing in the stability test of radiolabeling and the suggestions for further improvement are also addressed.

show abstract

Section: Radiolabeling Strategiesmentioning

confidence: 99%

Radiolabeling of Nanomaterials: Advantages and Challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

et al. 2023

View full text Add to dashboard Cite

Chemotherapy resistance remains a major cause of therapeutic failure in gastric cancer. The combination of genetic material such as interference RNAs (iRNAs) to silence cancer-associated genes with chemotherapeutics has become a novel approach for cancer treatment. However, finding the right target genes and developing non-toxic, highly selective nanocarrier systems remains a challenge. Here we developed a novel sialyl-Tn-targeted polylactic acid—didodecyldimethylammonium bromide nanoparticle (PLA-DDAB) nanoparticles (NPs) loaded with dsRNA targeting ST6GalNac-I and/or galectin-3 genes. Using single photon emission computed tomography (SPECT), we have demonstrated that 99mtechnetium radiolabeled sialyl-Tn-targeted nanoparticles can reach the tumor site and downregulate ST6GalNAc-I and galectin-3 RNA expression levels when injected intravenously. Furthermore, using an in vivo gastric tumor model, these nanoparticles increased the effectiveness of 5-FU in reducing tumor growth. Our findings indicate that cancer-associated glycan-targeted NPs loaded with dsRNA targeting ST6GalNAc-I and/or galectin-3 in combination with standard chemotherapy, have the potential to become a novel therapeutic tool for gastric cancer.

show abstract

Radiolabeling of Theranostic Nanosystems

Cited by 2 publications

References 71 publications

Radiolabeling of Nanomaterials: Advantages and Challenges

Radiolabeling of Nanomaterials: Advantages and Challenges

Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

Contact Info

Product

Resources

About